• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing

cafead

Administrator
Staff member
  • cafead   Oct 19, 2023 at 10:32: AM
via The Food and Drug Administration gave Intellia Therapeutics (NTLA) the go-ahead to begin a pivotal study of its gene-editing treatment for a deadly heart disease, but NTLA stock reversed its premarket gains.

article source
 

<